Compare DHC & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHC | ARCT |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 194.1M |
| IPO Year | N/A | N/A |
| Metric | DHC | ARCT |
|---|---|---|
| Price | $4.83 | $7.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $5.25 | ★ $38.67 |
| AVG Volume (30 Days) | 837.0K | ★ 892.4K |
| Earning Date | 11-03-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,537,901,000.00 | $97,601,000.00 |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | $3.32 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $2.00 | $5.85 |
| 52 Week High | $4.99 | $24.17 |
| Indicator | DHC | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 58.34 | 40.13 |
| Support Level | $4.65 | $7.04 |
| Resistance Level | $5.00 | $7.76 |
| Average True Range (ATR) | 0.14 | 0.39 |
| MACD | -0.01 | 0.37 |
| Stochastic Oscillator | 61.43 | 63.37 |
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs. Majority of revenue is from SHOP segment.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.